1.Wands JR., Chura CM., Roll FJ., Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975. 68:105–12.
Article
2.Jang JW. Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy. Korean J Med. 2012. 82:149–58.
Article
3.Lim SM., Jang JW., Kim BW., Choi H., Choi KY., Park SJ, et al. Hepatitis B vims reactivation during chlorambucil and prednisolone treatment in an HBsAg-negative and anti-HBs-positive patient with B-cell chronic lymphocytic leukemia. Korean J Hepatol. 2008. 14:213–8.
4.Rehermann B., Ferrari C., Pasquinelli C., Chisari FV. The hepatitis B virus persists for decades after patients'recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996. 2:1104–8.
5.Song SH., Hwang SG. Occult hepatitis B virus infection: transmission and reactivation. Korean J Gastroenterol. 2013. 62:148–53.
Article
6.Kusumoto S., Tanaka Y., Mizokami M., Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009. 90:13–23.
Article
7.Lee KS., Kim DJ. Korean Association for the Study of the Liver Guideline Committee. Management of Chronic Hepatitis B. Korean J Hepatol. 2007. 13:447–88.
8.Chung SM., Sohn JH., Kim TY., Yoo KD., Ahn YW., Bae JH, et al. Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B. Korean J Gastroenterol. 2010. 55:266–9.
Article
9.Gupta S., Govindarajan S., Fong TL., Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990. 12:562–8.
10.Yeo W., Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006. 43:209–20.
Article
11.Park JW., Park KW., Cho SH., Park HS., Lee WJ., Lee DH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol. 2005. 100:2194–200.
Article
12.Jang JW., Choi JY., Bae SH., Yoon SK., Chang UI., Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006. 43:233–40.
Article
13.Jung HM., Jun DW., Min JY., Doo EY., Nam KW., Kwon YI, et al. A Case of Acute Hepatitis B by Occult HBV Infection without HbsAg Seroconversion. Korean J Med. 2012. 83:619–23.
Article
14.Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol In. 2008. 2:152–62.
Article
15.Kusumoto S., Tanaka Y., Ueda R., Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011. 46:9–16.
Article
16.Lok AS., Liang RH., Chiu EK., Wong KL., Chan TK., Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991. 100:182–8.
17.Lau GK., Yiu HH., Fong DY., Cheng HC., Au WY., Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003. 125:1742–9.
Article
18.Tur-Kaspa R., Burk RD., Shaul Y., Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA. 1986. 83:1627–31.
Article
19.Kawsar HI., Shahnewaz J., Gopalakrishna KV., Spiro TP., Daw HA. Hepatitis B Reactivation in Cancer Patients; Role of Prechemotherapy Screening and Antiviral Prophylaxis. Clin Adv Hematol Oncol. 2012. 10:370–8.
20.Yeo W., Chan TC., Leung NW., Lam WY., Mo FK., Chu HL, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009. 27:605–11.
Article
21.The Korean Association for the Study of the Liver. Guidelines for Chronic hepatitis B [Internet]. Seoul: The Korean Association for the Study of the Liver;c2011. [cited 2011 DecOl]. Available from: http://www.kasl.org/html/sub05_03_l.asp.
22.Zelenetz Andew D.., Gordon Leo I.., Wierda William G.., Abramson Jeremy S.., Advani Ranjana H.., Babis Andreadis C., et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Cane Netw. Version 1. 2014.
23.Dervite I., Hober D., Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001. 344:68–9.
Article
24.Sera T., Hiasa Y., Michitaka K., Konshi I., Masuura K., Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006. 45:721–4.
Article
25.Kim EB., Kim DS., Park SJ., Park Y., Rho KH., Kim SJ. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat. 2008. 40:36–8.
Article